Yang J.-Y.,Wuxi Sinosbio Biomedicine Science and Technology Co. |
Jiao Y.-J.,Wuxi Sinosbio Biomedicine Science and Technology Co. |
Guo X.-L.,Wuxi Sinosbio Biomedicine Science and Technology Co. |
Xu D.-H.,Wuxi Sinosbio Biomedicine Science and Technology Co. |
And 5 more authors.
Chinese Journal of Biologicals | Year: 2014
Objective: To screen severe fever with thrombocytopenia syndrome Bunyavirus (SFTSV) vaccine candidate strain and lay a foundation of further preparation of vaccine. Methods: Vero cells which grew into a dense monolayer were inoculated with vaccine candidate strain, of which the supernatant was harvested while sufficiently pathological changes appeared. The strain for production of SFTSV vaccine was evaluated by five indexes, i.e. virus titer, antibody potency, antigen content, cross protection and stability during subculture, based on which a three-tier virus seed bank was established and identified. Results: Three second-round candidate strains were obtained after the first-round screening, of which strain JS-2011-013 was defined as the final candidate strain for vaccine production. All the quality indexes of established three-tier seed bank met the requirements in Chinese Pharmacopoeia (Volume III) (2010 edition). Conclusion: The SFTS Bunyavirus vaccine candidate strain was obtained successfully, which laid a foundation of further preparation of the vaccine.